Samsung Bioepis has teamed up with Takeda Pharmaceuticals to develop a number of biotherapy products for clinical treatment

On August 21st Samsung Bioepis said it had reached a strategic partnership agreement with Japan's Takeda Pharmaceuticals to jointly invest in and develop a number of biotherapy products for clinically unsolved disease treatments. At the same time, the two companies will soon embark on the first jointly developed candidate project for the treatment of acute severe pancreatitis, TAK-671.
Star Bioepis Chairman and CEO Christopher Hansung Ko said, "Takeda Pharmaceuticals' extensive expertise and hands-on experience in drug development makes it our ideal partner and opens up new developments for Samsung Bio. Five years ago, Samsung entered the biopharmaceutical industry with the determination to replace traditional processes and bring innovative therapies to patients. In partnership with Takeda Pharmaceuticals, we look forward to realizing our vision and accelerating the development of effective treatments for diseases that are still not available for effective treatment.
this risk-sharing collaboration brings together Samsung Bio's flexible biopharmaceity development platform and Takeda's best drug development scientists, both of which are responsible for the development of clinically valuable therapies. Other terms of cooperation were not disclosed.Dr Daniel Curran, Head of the External Innovation Center at
Takeda Pharmaceuticals, said: "Takeda Pharmaceuticals will think differently and creatively about our partners to make the partnership a success and build the strengths of our companies based on the complementary strengths of our partners. This partnership with Samsung Bioepis is undoubtedly a combination of our experience in drug development, production and clinical innovation, and we will maximize the potential for clinically valuable drugs.
Samsung BioLogics was founded in 2012, Samsung BioLogics has its own biosimilar pipeline, an early product line that includes therapeutic drugs for immunological diseases, cancer and diabetes, and is committed to growing into a global bio-company leader based on its innovative capabilities and quality management system, a joint venture between Samsung BioLogics and Baijian.
Biopharmaceuticals entered the biopharmaceutical industry by commissioning a CMO Manufacturing Organization project. Samsung Biopharmaceuticals has signed supply contracts with BMS in the United States and Roche in Switzerland, and is in talks with a number of biopharmaceutical companies to cooperate.